ConductScience.org, home

Paper17538164

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

Curran D and 11 others. J Clin Oncol, 2007. Cited by 185 papers, by iCite.

Cite this record

ConductScience Library. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. Papers, record 17538164. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538164

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
185
iCite
Relative citation ratio, by iCite
4.62
iCite
Revised in PubMed
2022-03-16
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Curran DDesmond
2Giralt JJordi
3Harari PMPaul M
4Ang KKK Kian
5Cohen RBRoger B
6Kies MSMerrill S
7Jassem JJacek
8Baselga JJosé
9Rowinsky EKEric K
10Amellal NNadia
11Comte SSylvie
12Bonner JAJames A

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic AgentsMajor topic
Carcinoma, Squamous CellMajor topic
ErbB ReceptorsMajor topic
Head and Neck NeoplasmsMajor topic
Quality of LifeMajor topic
Antibodies, Monoclonal, Humanized
Cetuximab
Health Status
Humans
Prognosis

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00700440Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With ChemoradiotherapyBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17538157Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.https://conductscience.org/library/papers/17538157

Source PubMed

Download CSV of comments and corrections

Cited by93

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.

PMIDTitleJournalYearIn PapersSource
41825810Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.Int J Radiat Oncol Biol Phys2026https://conductscience.org/library/papers/41825810PubMed
40214872Predictors of survival among head and neck cancer patients after radiotherapy based on health-related quality of life indices and symptoms-specific outcomes: a systematic review.Qual Life Res2025https://conductscience.org/library/papers/40214872PubMed
40162076The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy.J Inflamm Res2025https://conductscience.org/library/papers/40162076PubMed
39457986From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.J Clin Med2024https://conductscience.org/library/papers/39457986PubMed
39376987Improved quality of life in head and neck cancer patients treated with modern arc radiotherapy techniques - A prospective longitudinal analysis.Front Oncol2024https://conductscience.org/library/papers/39376987PubMed
39144266Radiation-induced skin injury in the head and neck region: pathogenesis, clinics, prevention, treatment considerations and proposal for management algorithm.Rep Pract Oncol Radiother2024https://conductscience.org/library/papers/39144266PubMed
38525491First Phase Development of a Patient-reported Outcome Measure for Midface Oncology.Plast Reconstr Surg Glob Open2024https://conductscience.org/library/papers/38525491PubMed
38436503Impact of Adjuvant Radiotherapy Setting on Quality-of-Life in Head and Neck Squamous Cell Carcinoma.Laryngoscope2024https://conductscience.org/library/papers/38436503PubMed
38193937Quality of life following treatment with intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.Support Care Cancer2024https://conductscience.org/library/papers/38193937PubMed
37992137Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.Med Oral Patol Oral Cir Bucal2024https://conductscience.org/library/papers/37992137PubMed
36683928Immunotherapeutic and their immunological aspects: Current treatment strategies and agents.Natl J Maxillofac Surg2022https://conductscience.org/library/papers/36683928PubMed
36001247
Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Int J Clin Oncol2022https://conductscience.org/library/papers/36001247PubMed
35836484Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study.Oncol Lett2022https://conductscience.org/library/papers/35836484PubMed
35463348Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up.Front Oncol2022https://conductscience.org/library/papers/35463348PubMed
35343648Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.Cancer Med2022https://conductscience.org/library/papers/35343648PubMed
35149773Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy.Sci Rep2022https://conductscience.org/library/papers/35149773PubMed
34285948Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer.Int J Part Ther2021https://conductscience.org/library/papers/34285948PubMed
33289866Health-related quality of life and overall survival: a prospective study in patients with head and neck cancer treated with radiotherapy.Qual Life Res2021https://conductscience.org/library/papers/33289866PubMed
32936912Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.Radiat Res2020https://conductscience.org/library/papers/32936912PubMed
32920767Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life.Qual Life Res2021https://conductscience.org/library/papers/32920767PubMed

See all 93 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17538164

GET https://conductscience.org/api/papers/v1/17538164/cited_by?page=2